Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency

Stefano Stagi*, Paolo Del Greco, Franco Ricci, Chiara Iurato, Giovanni Poggi, Salvatore Seminara and Maurizio de Martino

Abstract

Background: Primary adrenal insufficiency is relatively rare in children and, if unrecognized, may present with cardiovascular collapse, making it a potentially life-threatening entity.

Case presentation: The proposita, 11 months old of age, was admitted for lethargy and severe dehydration. Blood pressure was 62/38 mm Hg, and biochemical measurements showed hyponatraemia, hypochloraemia, hyperkalaemia, and metabolic acidemia. Renin activity was 1484 μU/mL; cortisol, 1.03 μg/dL (normal, 5-25 μg/dL); and corticotropin (ACTH), 4832 ng/L (normal, 9-52 ng/L). Adrenal deficiency was diagnosed, and replacement therapy with glucocorticoids and mineralocorticoids was initiated. After 40 days, ACTH was 797 ng/L. During follow-up, the patient started taking macrogol twice daily for constipation and experienced a significant increase in ACTH (3262 ng/L), which dropped to 648 ng/L when macrogol was stopped. After arbitrary reintroduction of macrogol, the child presented with hypoglycaemia, lethargy, weakness, and hypotonia; ACTH was 3145 ng/L. After again stopping macrogol, her ACTH was near normalized (323 ng/L).

Conclusion: Hydrocortisone malabsorption may be caused by macrogol use. Because chronic constipation is frequently reported in children, the possibility that macrogol contributes to adrenal crisis should be taken in account.

Keywords: Macrogol, Hydrocortisone, Adrenal insufficiency, Malabsorption, Polyethylene glycol, Constipation

Introduction

Adrenal insufficiency is relatively rare in children and may be categorized as primary or secondary and congenital or acquired [1]. Primary adrenal insufficiency can be caused by a deficiency in steroid biosynthesis or abnormal adrenal gland development. It is a life-threatening disorder that can result from primary adrenal failure or secondary adrenal disease resulting in impairment of the hypothalamic-pituitary axis. Prompt diagnosis and urgent mineralocorticoid and glucocorticoid replacement is mandatory [2]; however, correct management is also essential [3].

Chronic idiopathic constipation is frequently reported and reduces patient quality of life [4,5]. In fact, chronic constipation is associated with long-term problems including megarectum, reduced sensitivity of the rectum to the presence of faeces, and abnormal gut motility [4]. In many children, constipation is triggered by painful bowel movements caused by factors such as toilet training, changes in routine or diet, stressful events, intercurrent illness, or delaying defecation [4]. Therefore, managing chronic constipation in children effectively and early in its course is important in preventing long-term defecation disorders [4].

Polyethylene glycols (PEGs, or macrogols) are hydrophilic polymers of ethylene oxide [6] used in many drugs such as bowel preparations, dispersing agents, and excipients, and in cosmetics [7]. Water makes up 75-80% (wt/wt) of the normal stool, and a difference of only 10% in hydration results in marked changes in stool consistency [8]. Because PEG is a large molecular weight water-soluble polymer, it has the capacity to form hydrogen bonds with 100 molecules of water per molecule of PEG [9]. When PEG is administered orally, the resulting hydration of the

* Correspondence: stefano.stagi@yahoo.it
Department of Health Sciences, University of Florence, Anna Meyer Children’s University Hospital, Florence, Italy

© 2014 Stagi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
colonic content facilitates transit and painless defecation in a linear dose-dependent fashion [10]. Therefore, PEG-based laxatives, when used in escalating doses, can also be used to completely remove faecal loading in preference to rectally-administered treatments. Standard management of chronic constipation tends to begin with correction of dietary and lifestyle factors that predispose to the condition and focus on increasing dietary fibre and fluid intake [11]. Dietary manipulation alone, including the use of corn syrup, was successful in resolving all symptoms of constipation in 25% of children aged up to 2 years in one US study [5].

We describe a girl with adrenal insufficiency managed with hydrocortisone and fluorocortisone who showed an adrenal crisis after administration of macrogol 3350, and we discuss this aspect, focusing on the aetiology of adrenal insufficiency in childhood.

**Case report**

The proposita, 11 months old of age, was admitted to Anna Meyer Children’s University Hospital for lethargy and severe dehydration without history of vomiting or diarrhoea. She was the first child of non-consanguineous, young, healthy Italian parents, born at term (39 wks of gestation) by natural childbirth. Birth weight was 3200 g, body length, 51 cm (1.12 SDS, 75th-90th centile), and head circumference, 35 cm (1.04 SDS, 75th-90th centile). There were no perinatal problems or familial history of similar presentations or features of endocrine disease. Neuromotor development was normal; she was sitting at 5 months. At 10 months, 20 days of age, she started showing weight loss, lethargy, weakness, hypotonia, and dark skin. She was mildly dehydrated. Her body weight, length, and head circumference were 10.850 kg (1.89 SDS, 97th centile), 73 cm (0.61 SDS, 50th-75th centile), and 46.5 cm (1.30 SDS, 90th centile), respectively. There were no dysmorphic features. External genitalia were normal female type with no ambiguity. There was no abdominal or inguinal mass discovered upon abdominal examination. Blood pressure was 62/38 mm Hg; respiration, 35/min; pulse, 121/min; and body temperature, 37.3°C.

Biochemical measurements indicated hyponatraemia (Na, 125 mEq/L), hypochloraemia (Cl, 86 mEq/L), hyperkalaemia (K, 5.7 mEq/L), metabolic acidemia by arterial venous blood gas, elevated serum urea nitrogen (60 mg/dL), and normal creatinine (0.3 mg/dL). Glucose was 56 mg/dL (normal, 55-110 mg/dL). An extensive endocrine workup, carried out at 8 AM after an overnight fast, showed free thyroxin was 1.27 ng/dL (normal, 0.80-1.90 ng/dL); thyrotropin, 3.96 μU/mL (normal, 0.4-4.0 μU/mL); aldosterone, 0.19 nmol/L (normal, 0.96-8.31 nmol/L); renin activity, 1484 μU/mL per h (normal, 2-10.2 μU/mL per h); 17-OH-progesterone, < 0.5 nmol/L; dehydroepiandrosterone sulfate, < 15 μg/dL; cortisol, 1.03 μg/dL (normal, 5-25 μg/dL); ACTH, 4832 ng/L (normal, 9-52 ng/L; Figure 1), luteinizing hormone, 2.3 IU/L; and follicle stimulating hormone, 5.6 IU/L.

Serum cortisol and plasma ACTH levels were measured routinely using an Immulite 2000 chemiluminescence immunometric assay (Diagnostic Products Corporation, xLos Angeles, CA, USA). The cortisol inter-assay and intra-assay coefficients of variation were < 9.5% and 7.4%, respectively. The ACTH inter-assay and intra-assay coefficients of variation ranged from 6.1% to 10.0% and from 6.7% to 9.5%, respectively.

The patient was hydrated with normal saline and required vasopressors. Adrenal deficiency was diagnosed considering the hyponatraemia, hyperkalaemia, metabolic acidemia, and cortisol and corticotropic levels.

The usual causes of primary adrenal insufficiency were ruled out (Table 1). Family history was negative for autoimmune diseases and endocrinological or genetic syndromes. Renal Doppler ultrasonography was performed and was normal. Autoimmune Addison, in the context of autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) or other autoimmune syndromes was ruled out by clinical and biochemical evaluation. Mantoux was negative and Veneral Disease Research Laboratory (VDRL) was non-reactive. Human immunodeficiency virus was seronegative. Plasma levels of very long chain fatty acids (VLCFAs) were normal. We performed a synthetic ACTH stimulation test intravenously at 8 AM after an overnight fast, and the cortisol response, measured at 0, 30, and 60 minutes after infusion was blunted (0.98, 1.39, and 2.01 μg/dL, respectively). An MRI scan of the bilateral adrenal glands revealed agenesis of the right and hypoplasia of the left adrenal glands (Figures 1A and B).

Replacement therapy with standard doses of glucocorticoid (hydrocortisone, 15 mg/m²/day), mineralocorticoid (fluorocortisone, 0.2 mg/day), and sodium chloride (NaCl, 1 g/day) was initiated.

Routine cytogenetic investigations revealed an apparently normal female karyotype (46, XX). Molecular karyotyping was performed using an array comparative genomic hybridization analysis using proband’s DNA and a 44 K array platform (Agilent Technologies) with a resolution of approximately 100 kilobase. This examination yielded normal results.

After replacement therapy, electrolyte abnormalities were corrected during the first week, and the patient was discharged in good clinical condition. During follow-up, she maintained good condition, good appetite, weight gain, and normal laboratory results with reduced ACTH (Figure 2). After 10 days, ACTH was 3214 ng/L; renin activity, 165.3 μU/mL; Na, 139 mEq/L; K, 4.4 mEq/L; and Cl, 96 mEq/L, and after 40 days ACTH was 797 ng/L.
At 14 months of age, the patient started taking macrogol twice daily for constipation, about 30 to 60 minutes after taking hydrocortisone and fluorocortisone. Testing revealed that ACTH was 300 ng/L, and renin activity was 24.2 μU/mL. Analysis of the SFI gene was normal with the exception of a c.437G > C polymorphism.

After 3 months of macrogol therapy, Na was 135 mEq/L; Cl, 106 mEq/L; K, 5.3 mEq/L; renin activity, 124.2 μU/mL; aldosterone, 0.13 nmol/L; cortisol, 1.78 μg/dL; and ACTH, 3262 ng/L. The macrogol was stopped, resulting in a rapid reduction of corticotropin; after 28 days it was 648 ng/L. At this time, faecal elastase was 548 μg/g (normal, >200 μg/g), and steatocrit was 0% (normal, <3%). Screening for celiac disease was negative (IgA, 38 mg/dL; tTG, 1.0 U/mL).

Unfortunately, the family arbitrarily reintroduced macrogol (once daily, more than 2 hours after taking hydrocortisone and fluorocortisone) for chronic constipation. After 1 month, during a respiratory tract infection, the child presented with hypoglycaemia, lethargy, weakness, and hypotonia. Vitals were measured: pulse, 134/min; blood pressure, 65/42 mm Hg; and respiration, 38/min. Glucose was 36 mg/dL; Na, 132 mEq/L; Cl, 92 mEq/L; K, 5.4 mEq/L; and ACTH, 3145 ng/L. During recovery, we treated the adrenal deficiency and stopped the macrogol with near normalization of corticotropin (323 ng/L) after 23 days (Figure 2). Neuro-metabolic tests (plasma aminoacidogram, urine aminoacidogram, acylcarnitine profile analysis, and redox state) were again normal.

**Discussion**

A variety of laxatives are available for treating constipation: bulk forming, osmotic, and stimulant laxatives. Osmotic laxatives, particularly PEG preparations, are popular because they are relatively safe, inexpensive, and better than lactulose in improving stool frequency and consistency [12-14]. Hydrocortisone is a hydrophilic drug used to treat many conditions, such as primary or secondary adrenal insufficiency, hypopituitarism, and adrenogenital syndrome.

Nevertheless, treatment of children suffering from adrenal insufficiency is frequently problematic for a number of reasons. For example, it requires use of pharmaceutical formulations that do not fully address the pharmacokinetic and pharmacodynamic problems of dosing infants. Therefore, children require careful monitoring of dose and dosage regimen. In fact, patients with adrenal insufficiency continue to have increased mortality and morbidity despite treatment and monitoring [15]. However, many drugs, for example, anticonvulsants such as phenytoin, phenobarbital, and carbamazepine, stimulate cytochrome P450 3A4, induce hepatic enzymes, and lead to accelerated glucocorticoid metabolism and reduced glucocorticoid effect, possibly causing acute adrenal insufficiency [16].
### Table 1 Typical causes of primary adrenal insufficiency

| 1) Genetic disorders                                      | OMIM<sup>1</sup>          | Etiologic mechanisms                                      | Other signs and symptoms                                                                 |
|-----------------------------------------------------------|---------------------------|-----------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Adrenoleukodystrophy                                      | 300100 (Xq28)             | Mutations of ABCD<sup>1</sup>, ABCD<sup>2</sup>           | Weakness, diminished visual acuity, deafness, cerebellar ataxia, hemiplegia, convulsions, dementia |
| Congenital adrenal hyperplasia                             |                           |                                                           |                                                                                            |
| 21-hydroxylase deficiency                                 | 201910 (6p21.33)          | Mutations of CYP21A<sup>2</sup>                           | Hyperandrogenism, ambiguous genitalia in females                                            |
| 11β-hydroxylase deficiency                                | 202010 (8q24.3)           | Mutations of CYP11B<sup>1</sup>                           | Hyperandrogenism, hypertension                                                              |
| 3β-hydroxysteroid dehydrogenase type 2 deficiency         | 201810 (1p12)             | Mutations of HSD3B2<sup>3</sup>                           | Ambiguous genitalia in boys, postnatal virilisation in girls                               |
| 17α-hydroxylase deficiency                                | 202110 (10q24.32)         | Mutations of CYP17A1<sup>4</sup>                          | Pubertal delay in both sexes, primary amenorrhea, lack of secondary sexual characteristics, hypertension |
| P450 oxidoreductase deficiency                            | 201750 (7q11.23)          | Mutations of P450<sup>5</sup>                            | Skeletal malformations, especially craniofacial; severe abnormal genitalia                 |
| P450 side-chain cleavage deficiency                       | 613743 (15q24.1)          | Mutations of CYP11A1<sup>7</sup>                         | XY sex reversal                                                                           |
| Congenital lipid adrenal hyperplasia                      | 201710 (8p11.23)          | Mutations of STAR<sup>8</sup>                            | XY sex reversal                                                                           |
| Smith-Lemli-Opitz syndrome                                | 270400 (11q13.4)          | Mutations of DHCR7<sup>11</sup>                          | Mental retardation, craniofacial malformations, growth failure, cholesterol deficiency     |
| Adrenal hypoplasia congenita                               |                           |                                                           |                                                                                            |
| X-linked                                                  | 300200 (Xp21.2)           | Mutations of NR0B1<sup>12</sup>                          | Hypogonadotropic hypogonadism in boys (occasionally in carrier females for skewed X-chromosome inactivation) |
| Xp21 deletion syndrome                                    | 300679 (Xp21)             | Deletion of GK<sup>13</sup>, DMD<sup>14</sup>, and NR0B1  | Duchenne muscular dystrophy, glycerol kinase deficiency psychomotor retardation             |
| SF1-linked                                                | 612965 (9q33.3)           | Mutations of NRSAPI<sup>15</sup>                         | XY sex reversal                                                                           |
| IMAGe syndrome                                            | 614732 (11p15.4)          | Mutations of CDKN1C<sup>16</sup>                        | Intrauterine growth retardation, metaphyseal dysplasia, genital abnormalities               |
| Kearns-Sayre syndrome                                     |                           | Deletions of mitochondrial DNA                            | Deafness; heart, ocular and cerebral involvement; skeletal muscle myopathy; intestinal disorders; hormonal deficits |
| Wolman disease                                            | 278000 (10q23.31)         | Mutations of LIPA<sup>17</sup>                           | Bilateral adrenal calcification, hepatosplenomegaly                                         |
| Sitosterolaemia                                           |                           | Mutations of ABCG5<sup>18</sup> and ABCG8<sup>19</sup>   | Xanthomata, arthritis, premature coronary artery disease, short stature, gonadal failure    |
| Familial glucocorticoid deficiency or corticotropin insensitivity syndromes | | | |
| Type 1                                                    | 202200 (18p11.21)         | Mutations of MC2R<sup>20</sup>                           | Hyperpigmentation, tall stature, typical facial features, lethargy and muscle weakness with normal blood pressure |
| Type 2                                                    | 607398 (21q22.11)         | Mutations of MRAP<sup>21</sup>                           | Hyperpigmentation, normal height, hypoglycaemia, lethargy, and muscle weakness with normal blood pressure |
| Variant of familial glucocorticoid deficiency             | 609981 (8q11.21)          | Mutations of MCM4<sup>22</sup>                           | Growth failure, increased chromosomal breakage, natural killer cell deficiency               |
| Primary generalised glucocorticoid resistance             | (5q31.3)                  | Mutations of GCCR<sup>23</sup>                           | Fatigue, hypoglycaemia, hypertension, hyperandrogenism                                      |
| Triple A syndrome (Allgrove’s syndrome)                  | 231550 (12q13.13)         | Mutations of AAAS<sup>24</sup>                           | Achalasia, alacrima, deafness, mental retardation, hyperkeratosis                          |

| 2) Acquired diseases                                      |                           |                                                           |                                                                                            |
| Bilateral adrenal haemorrhage                             | -                         | Meningococcal sepsis, antiphospholipid syndrome           | Symptoms and signs of underlying disease                                                    |
| Bilateral adrenal metastases                              | -                         | Lung, stomach, breast, and colon cancers                 | Disease-associated clinical manifestations                                                  |
Hydrocortisone preparations are commonly combined with pharmaceutically acceptable carriers, typically inert, to facilitate their administration. Polyethylene glycol contains a mixture of inert water-soluble molecules of different sizes, whose absorption is independent of dosage, displaying decreasing mucosal transport with increasing molecular size. Macrogol solutions are commonly used for their efficacy and low rate of absorption (0.2%) after oral administration [17] and typically have a safe profile with minimal reported side effects.

Table 1 Typical causes of primary adrenal insufficiency (Continued)

| Cause | Symptoms and signs of underlying disease | Disease-associated clinical manifestations | Disease-associated manifestations in other organs |
|-------|----------------------------------------|------------------------------------------|-----------------------------------------------|
| Bilateral adrenalectomy | Adrenal masses, phaeochromocytoma unresolved Cushing’s syndrome | | |
| Bilateral adrenal infiltration | Adrenal lymphoma, amyloidosis, haemochromatosis | | |
| Drug-induced adrenal insufficiency | Anticoagulants, ketoconazole, fluconazole, etomidate, phenobarbital, phenytoin, rifampicin, troglitazone | None, unless related to drug | |
| Infectious adrenalitis | Tuberculosis, HIV-1, histoplasmosis, cryptococcosis, coccidioidomycosis, syphilis, trypanosomiasis | | |
| Autoimmune adrenalitis | Isolated | None | |
| APS type 1 (APECED) | | Chronic mucocutaneous candidosis, hypoparathyroidism, other autoimmune diseases | |
| APS type 2 | 240300 (21q22.3) | Mutations of AIRE<sup>25</sup> | Thyroid autoimmune disease, type 1 diabetes, other autoimmune diseases |
| APS type 4 | 269200 | | Autoimmune gastritis, vitiligo, coeliac disease, alopecia, excluding thyroid disease and type 1 diabetes |

Modified by Charmandari et al., 2014 [16]: 1OMIM: Online Mendelian Inheritance in Man database; 2ABCD1: atp-binding cassette subfamily D, member 1; 3ABCD2: atp-binding cassette, subfamily D, member 2; 4CYP21A2: cytochrome P450, family 21, subfamily A, polypeptide 2; 5CYP11B1: cytochrome P450, family 11, subfamily B1, polypeptide 1; 6CYP11B2: 3-beta-hydroxysteroid dehydrogenase 2; 7CYP17A1: cytochrome P450, family 17, subfamily A1, polypeptide 1; 8POR: cytochrome P450 11a oxidoreductase; 9CYP11A1: cytochrome P450, subfamily X1A, polypeptide 1; 10STAR: steroidalogenic acute regulatory protein; 11DHCR7: 7-dehydrocholesterol reductase; 12NR0B1: nuclear receptor subfamily 0, group B, member 1; 13GK: glycerol kinase; 14DMD: dystrophin; 15NRS1A1: nuclear receptor subfamily 5, group A, member 1; 16CDKN1C: cyclin-dependent kinase inhibitor 1C; 17LIPA: lipase A, lysosomal acid; 18MC2R: melanocortin 2 receptor; 19MRAP: melanocortin 2 receptor accessory protein; 20MCM4: minichromosome maintenance, Saccharomyces Cerevisiae, homolog of; 21GCCR: glucocorticoid receptor; 22AAAS: AAAS GENE; 23AIRE: autoimmune regulator.

Figure 2 Corticotropin (ACTH) serum levels (ng/L) at diagnosis of adrenal insufficiency and the start of hydrocortisone (10 months, 20 days of age), after the start of macrogol (14 and 18 months of age), and after the termination of macrogol (17 and 19 months of age).
A drug’s solubility in water is an important factor influencing its release into the body. In addition, macrogol softens the faecal mass by osmotically drawing water into the GI tract. As our case showed, it is possible that macrogol reduces the absorption of hydrocortisone, facilitating the appearance of adrenal insufficiency. The case seems to support our hypothesis, considering the significant changes in corticotropin after starting and stopping macrogol. Furthermore, we could also speculate that the introduction of macrogol close to that of hydrocortisone or fluorocortisone could cause or contribute to the reduced absorption of these drugs, triggering the adrenal crisis. In fact, it is recognised that many physiological gastrointestinal factors may strongly influence the plasma concentration-time profile of hydrocortisone. However, hydrocortisone has a high permeability in both the small and large intestines, and the short elimination half-life (near 1.5 h) requires two or more dose administrations per day.

This aspect is of great concern because patients with primary or secondary adrenal insufficiency have more than twofold increased mortality than the general population. However, recent data have demonstrated that the metabolic cardiovascular risk in hypopituitarism is related to the daily dose of hydrocortisone.

Our case report, while not demonstrating a genetic aetiology (polymorphism of SF1 was the only abnormality), gives evidence of a possible genetic primary cause of adrenal insufficiency, based on clinical and laboratory examinations and the age of onset. In children, congenital primary adrenal insufficiency is very rare, accounting for about 1% of all cases. The importance of elucidating a genetic basis is emphasised by the ever-increasing number of genetic causes of adrenal insufficiency (Table 1). In fact, in a series of 103 children with Addison’s disease, genetic forms were very frequent, accounting for 72% of congenital adrenal hyperplasia; other genetic causes accounted for 6%, whereas autoimmune disease was diagnosed in only 13%.

As stressed by this case, prompt diagnosis is also important because acute adrenal insufficiency is a life threatening disease. Typically, patients with this disease present with severe hypotension to hypovolaemic shock, vomiting, acute abdominal pain, and often fever. However, children often present with hypoglycaemia and hypoglycaemic seizures. On the other hand, the primary non-specific symptoms of chronic adrenal insufficiency in children are fatigue, reduced muscle strength, weight loss, anorexia, or failure to thrive.

Conclusions
This case report suggests that macrogol 3350 could interfere with the absorption of hydrocortisone. It is of particular importance considering the risk of adrenal insufficiency in these patients, and careful attention should be paid to the concomitant use of macrogol and hydrocortisone in subjects with primary or secondary glucocorticoid deficiencies.

Consent
Written informed consent was obtained from the parents of the patient for publication of this Case Report and any accompanying images.

Competing interest
The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.

Authors’ contributions
Stagi: conception and design, endocrinological evaluation, manuscript writing and final approval of the manuscript. FR: data collection and analysis, manuscript writing and final approval of the manuscript. POG: data collection and analysis, manuscript writing and final approval of the manuscript. Cl: endocrinological evaluation, data collection and analysis, manuscript writing and final approval of the manuscript. GP: data collection and analysis, critical revision and final approval of the manuscript. SSeminara: endocrinological evaluation, critical revision and final approval of the manuscript. MdM: critical revision and final approval of the manuscript. All authors read and approved the final manuscript.

Acknowledgment
We thank Prof. Paolo Lionetti for an invaluable help in revising our manuscript.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Received: 9 June 2014 Accepted: 4 September 2014
Published online: 26 September 2014

References
1. Shulman DI, Palmert MR, Kemp SF, Lawson Wilkins Drug and Therapeutics Committee: Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007, 119(3):e484–e494.
2. Evlyajooglu O, Dokurel I, Buuck F, Ozcabi B, Ercan O, Ceylaner S: Primary adrenal insufficiency caused by a novel mutation in DAX1 gene. J Clin Res Pediatr Endocrino 2013, 5:S5–S7.
3. Charrandari E, Nicolaidis NC, Chrousos GP: Adrenal insufficiency. Lancet 2014, pii:S0140–5213(13).
4. Candy D, Belsey J: Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review. Arch Dis Child 2009, 94:156–160.
5. Loening-Baucke V: Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr 2005, 146:359–363.
6. Sany C, Vandenpluто O, Sibille Y: Usefulness of oral macrogol challenge in anaphylaxis after intra-articular injection of corticosteroid preparation. Allergy 2008, 63:478–479.
7. Napke E, Stevens DG: Excipients and additives: hidden hazards in drug products and in product substitution. CMAJ 1984, 131:1449–1452.
8. Bernier DJ, Donazzolo Y: Effect of low-dose polyethylene glycol 4000 on fecal consistency and dilution water in healthy subjects. Gastroenterol Clin Biol 1997, 21:7–11.
9. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS: Osmotic effects of polyethylene glycol. Gastroenterology 1998, 94:935–941.
10. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS: Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1980, 66:1056–1062.
11. Corazziari E: Need of the ideal drug for the treatment of chronic constipation. Ital J Gastroenterol Hepatol 1999, 31(Suppl 3):S232–S233.
12. Belsey JD, Geraint M, Dixon TA: Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010, 64:944–955.
13. Taylor RR, Guest JF: The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. Aliment Pharmacol Ther 2010, 31:302–312.
14. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL: Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 2010, 7:CD007570.
15. Grossman A, Johansson G, Quinkler M, Zelissen P: Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 2013, 169:165–T175.
16. Chamandari E, Nicolaides NC, Chrousos GP: Adrenal insufficiency. The Lancet 2014, 383:2152–2167.
17. Tooson JD, Gates LK Jr: Bowel preparation before colonoscopy. Choosing the best lavage regimen. Postgrad Med 1996, 100:203–214.
18. Lennernäs H, Skrlec S, Johansson G: Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opin Drug Metab Toxicol 2008, 4:749–758.
19. Perry R, Kecha O, Paquette J, Huot C, Van Wiet G, Deal C: Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 2005, 90:3243–3250.
20. Avgerinos PC, Cutler GB Jr, Tsokos GC, Gold PW, Feuillan P, Gallucci WT, Pillemier SR, Loriaux DL, Chrousos GP: Dissociation between cortisol and adrenal androgen secretion in patients receiving alternate day prednisone therapy. J Clin Endocrinol Metab 1987, 65:24–29.

doi:10.1186/s13052-014-0078-2
Cite this article as: Stagi et al.: Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency. Italian Journal of Pediatrics 2014 40:78.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution